Tarsons Products Limited — Investor Meet, 20-02-2025: Analysts/Institutional Investor Meet/Con. Call Updates

1. **Financial Performance:** For Q3 FY25, Tarsons Products achieved standalone revenues of ₹76.2 crores, up 23.3% YoY from ₹61.8 crores. This marks the highest revenue recorded for the third quarter in the company's history. Consolidated revenue reached ₹95.7 crores, boosted by the acquisition of Nerbe, which contributed ₹19.5 crores. Standalone EBITDA rose to ₹27.9 crores, reflecting a 21.9% increase YoY, though margin slightly declined to 36.7%. Profit after tax (PAT) stood at ₹7.6 crores, leading to a PAT margin of 10%. For the nine months ending December 2024, total revenue was ₹221 crores, showing a 16% YoY growth.

2. **Future Outlook and Growth Drivers:** Management is optimistic about sustained growth in the labware sector driven by rising research activities in life sciences. The company aims to enhance its international presence, leveraging participation in global trade fairs. They plan to optimize costs with the new Panchla facility expected to ramp up by H1 FY26, allowing for significant capacity and operational efficiencies.

3. **Order Book and Operational Updates:** The Panchla facility is under development, with commercial production for select products already underway. Management anticipates ramping up operations and improving margins as the facility reaches full capacity over the next 3–4 years.

4. **Analyst Q&A Insights (Detailed):**

- **Revenue and Profitability:** Analysts discussed the current depreciation impacting margins, which could stabilize around ₹60 crores by FY26. Management expressed confidence in improving PAT margins to 18-20% post-ramp-up.

- **Market Position and Competitive Landscape:** Management indicated that while domestic competition remains strong, they expect to gain market share through quality and operational improvements.

- **Operational Challenges or Risks:** Analysts raised concerns about the impact of rising fixed costs, but management assured them of improvements in cost absorption as production scales.

- **Capex and Capital Allocation:** Future capital allocation focuses on scaling the Panchla facility and enhancing product offerings without overextending the financials.

- **Strategic Priorities and Long-Term Vision:** Management outlined a multi-year plan to introduce advanced product lines to capitalize on market opportunities and expects gradual annual revenue increases.

5. **Market or Regulatory Updates:** No significant regulatory impacts were discussed, but management emphasized analyzing broader market trends to navigate competitive pressures effectively.

6. **Strategic Focus Areas:** The call highlighted a clear focus on expanding domestic market share and enhancing product innovation. The optimism about capturing a significant share of the global plastic labware market was evident.

7. **Investor Insight:** The financial health and growth potential of Tarsons Products indicate a favorable trajectory. With ongoing operational improvements and strategic market positioning, a ‘buy’ position appears justifiable, conditioned on the company executing its plans effectively and managing profitability.